Detection of Solitary Pelvic Lymph Node Metastasis in a Patient with Primary Prostate Cancer

Walter Noordzij, MD, PhD; Ronald Borra, MD, PhD; and Partha Ghosh, MD
Data Courtesy of University Medical Center Groningen, Groningen, The Netherlands

A 78-year-old male with a medical history of lower urinary tract symptoms, referred for primary staging of his newly diagnosed Gleason 3+4 prostate cancer, underwent a 68Ga PSMA PET/CT for initial staging on Biograph Vision™. The patient was intravenously injected with 2.7 mCi (100 MBq) of 68Ga PSMA, and the PET/CT study was performed 1 hour and 45 minutes post injection. The examination began with an ultra low-dose CT (100 kV, 16 eff mAs, 32 x 1.2 mm collimation) followed by a PET acquisition with continuous bed motion (FlowMotion™ technology) at a constant table speed of 1.0 mm/sec. The PET study was reconstructed with a 220 x 220 matrix using time of flight (ToF) and point spread function (PSF).

MIP images of 68Ga PSMA PET, from Biograph Vision, show a small focal uptake that is suggestive of a solitary lymph node metastasis.
Figure 1

The 68Ga PSMA PET/CT (Figures 1-3) shows a solitary right external iliac lymph node metastasis along with the PSMA-avid primary prostatic tumor without evidence of any other skeletal, soft tissue, or extrapelvic nodal metastases. The primary prostatic tumor showed a high-intensity uptake of 68Ga PSMA with a SUVmax of 41.2. The 6 mm solitary pelvic nodal metastasis had a SUVmax of 5.8 with high lesion-to-background ratio seen on the PET images, which helped differentiate the lesion from surrounding uptake in the ureter and intestines. The 68Ga PSMA PET/CT was instrumental in detecting a solitary pelvic lymph node metastasis in this patient with primary prostate cancer who otherwise had no clinical or radiological suspicion of metastases. Detection of a single metastatic lymph node puts the patient in stage IV, irrespective of the Gleason score or PSA level.

PET, CT, and fused images, from Biograph Vision, display high uptake of 68Ga PSMA in the primary prostatic tumor and lymph node metastasis.
Figure 2

The 68Ga PSMA PET/CT was instrumental in accurately staging this patient who was otherwise clinically considered free of nodal or distant metastases. Detection of a solitary PSMA-expressing nodal metastasis by the 68Ga PSMA PET/CT scan places the patient in stage IV; such staging leads to a significant change in therapy approach regarding the use of androgen deprivation therapy (ADT). The detection of a small lymph node metastasis (6 mm in diameter on CT) reflects the high sensitivity of the 68Ga PSMA PET/CT for detection of nodal metastases. High ToF performance on Biograph Vision demonstrates a possible key relevance for such sharp delineation of a 6 mm lymph node metastasis with high lesion-to-background ratio. Increased contrast to background in any nodal lesion helps distinguish a metastasis from adjacent soft tissue and physiological uptake in the intestines. Excellent ToF performance, high resolution, and count-rate capability available with Biograph Vision should have a positive impact in improving the accuracy of staging since the detectability of small metastatic lesions is a key driver in the staging of prostate cancer.

Enlarged views of CT and fused PET/CT images, from Biograph Vision, show a solitary lymph node metastasis.
Figure 3

The primary prostatic tumor in this patient shows high PSMA avidity with a high SUVmax of 41.2. Primary tumors with higher PSMA uptake and SUV have been shown to be associated with higher serum PSA levels and a higher Gleason score.1 In this case, the 41.2 SUVmax in the primary tumor probably reflects a higher Gleason score.
68Ga PSMA PET/CT has shown high sensitivity for detection of nodal metastases, as reflected by a study, which demonstrated detection rates of 57.9% in patients with mild post-surgery PSA increase to the level of 0.2-0.5 ng/ml.2 In another study involving 50 newly diagnosed prostate cancer patients without any previous treatment history, 68Ga-PSMA-11 PET/CT detected lymph node metastases in 16% of patients and distant metastases in 10% of patients.3 In 13 of these 50 patients (26%), there was a change in staging with 11 of the 13 patients (84%) upstaged based on 68Ga PSMA PET/CT. There was an alteration in the treatment plan in 44% of this patient group.

The present report reflects the sensitivity of 68Ga PSMA PET/CT for the detection of lymph node metastases and the potential impact on staging and management. Technological improvements in PET/CT, such as the incorporation of Silicon Photomultiplier (SiPM) technology—which leads to an improvement in ToF performance—may potentially prove instrumental in demonstrating PET/CT’s impact in staging and managing prostate cancer.
Biograph Vision, with 214-picosecond timing resolution, enables high lesion contrast to background with standard acquisition time in spite of low injected dose and long post-injection delay. Such a high lesion-to-background ratio improves small metastatic lymph node detectability. Partial volume effect can impact the detection of lymph node metastases as small as 6 mm with low uptake demonstrated by a relatively small SUVmax of 5.8, as seen in this case. The 3.2 mm crystals in Biograph Vision provide high spatial resolution, which help minimize partial volume effects thereby providing sharp delineation of such a small lesion along with a high lesion-to-background ratio for excellent small lesion visibility and quantitative accuracy.

The sharp definition and high lesion-to-background ratio provided by advanced SiPM PET/CT technology, enables the visualization of a solitary 6 mm pelvic lymph node metastasis with relatively low uptake of 68Ga PSMA in a patient with primary prostate cancer. The ability to visualize a singular lymph nodal metastasis led to a major change in the patient’s staging-associated therapy implications.



Injected dose

2.7 mCi (100 MBq)


FlowMotion 1.0 mm/sec, 220 x 220 matrix



Slice collimation

32 x 1.2 mm

Tube voltage

100 kV

Tube current

16 eff mAs

Slice thickness

3 MM